drugset / Trial / NCT00293345
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma. Drugs used in chemotherapy, such as 3-AP and gemcitabine (GEM), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. 3-AP may help gemcitabine kill more cancer cells by making the cells more sensitive to the drug. 3-AP may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2006-06
- Primary completion
- 2012-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triapine | Small molecule | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
Indications
Burkitt lymphoma
Hodgkins lymphoma
MALT lymphoma
Waldenstrom macroglobulinemia
adult T-cell leukemia/lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
cancer of unknown primary site
central nervous system non-hodgkin lymphoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
diffuse large B-cell lymphoma
intraocular lymphoma
large-cell immunoblastic lymphoma
mantle cell lymphoma
mycosis fungoides and variants
nodal marginal zone B-cell lymphoma
small intestine lymphoma
splenic marginal zone lymphoma